These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1674023)

  • 21. Animal models of systemic vasculitis.
    Mathieson PW; Qasim FJ; Esnault VL; Oliveira DB
    J Autoimmun; 1993 Apr; 6(2):251-64. PubMed ID: 8388693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between disease activity and ANCA level by ELISA in the long-term management of vasculitis.
    De'Oliviera J; Gaskin G; Dash A; Rees AJ; Pusey CD
    Adv Exp Med Biol; 1993; 336():303-4. PubMed ID: 8296622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal disease associated with antineutrophil cytoplasmic antibody: 39 patients over a 5-year period.
    Jeffrey RF; Khan AA; Davison A; Aparicio S; Gooi HC; Will EJ; Davison AM
    Br J Clin Pract; 1994; 48(4):180-4. PubMed ID: 7917796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
    Ozaki S
    Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ANCA and predicting relapse in systemic vasculitis.
    Jayne DR; Gaskin G; Pusey CD; Lockwood CM
    QJM; 1995 Feb; 88(2):127-33. PubMed ID: 7704563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New treatment strategies for systemic vasculitis: the role of intravenous immune globulin therapy.
    Lockwood CM
    Clin Exp Immunol; 1996 May; 104 Suppl 1():77-82. PubMed ID: 8625549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preliminary results of intravenous immunoglobulins in treating patients with vasculitis].
    Antonelli A; Agostini G; Agostini S
    Clin Ter; 1992 Sep; 141(9 Pt 2):33-6. PubMed ID: 1468195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients.
    Wendt M; Gunnarsson I; Bratt J; Bruchfeld A
    Scand J Rheumatol; 2012 Mar; 41(2):116-9. PubMed ID: 22118245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic and pathogenic significance of antineutrophil cytoplasmic antibodies in vasculitides].
    Bartůnková J; Tesar V; Fucíková T; Janatková I; Zabka J; Krystůfková O; Rychlík I
    Bratisl Lek Listy; 1995 Oct; 96(10):528-33. PubMed ID: 8620323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
    Eriksson P
    J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic effect and clinical findings in patients with MPO-ANCA associated vasculitis syndrome].
    Yoshida A; Takeda A; Fukuda M; Toda S; Morozumi K
    Ryumachi; 2000 Feb; 40(1):1-8. PubMed ID: 10783659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis.
    Lin W; Chen M; Zhao MH
    Autoimmunity; 2009 Mar; 42(3):198-202. PubMed ID: 19301200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two sisters with ANCA positive vasculitis.
    Murphy EA; Sturrock RD; Fox JG; Boulton-Jones JM
    Ann Rheum Dis; 1993 May; 52(5):385. PubMed ID: 8323389
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical outcome of patients with coexistent antineutrophil cytoplasmic antibodies and antibodies against glomerular basement membrane.
    Lindic J; Vizjak A; Ferluga D; Kovac D; Ales A; Kveder R; Ponikvar R; Bren A
    Ther Apher Dial; 2009 Aug; 13(4):278-81. PubMed ID: 19695059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
    Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
    Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
    Pullerits R; Ljevak M; Vikgren J; Bokarewa M
    Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immunoglobulin (IVIg) therapy in MPO-ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan.
    Muso E; Ito-Ihara T; Ono T; Imai E; Yamagata K; Akamatsu A; Suzuki K
    Jpn J Infect Dis; 2004 Oct; 57(5):S17-8. PubMed ID: 15507757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis.
    Jayne DR; Weetman AP; Lockwood CM
    Clin Exp Immunol; 1991 Jun; 84(3):476-81. PubMed ID: 2044229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
    Harper L; Morgan MD; Walsh M; Hoglund P; Westman K; Flossmann O; Tesar V; Vanhille P; de Groot K; Luqmani R; Flores-Suarez LF; Watts R; Pusey C; Bruchfeld A; Rasmussen N; Blockmans D; Savage CO; Jayne D;
    Ann Rheum Dis; 2012 Jun; 71(6):955-60. PubMed ID: 22128076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [High dosage intravenous immunoglobulin (IVIG) therapy in therapy-refractory ANCA-negative, necrotizing vasculitis].
    Altmeyer P; Seifarth D; Bacharach-Buhles M
    Hautarzt; 1999 Dec; 50(12):853-8. PubMed ID: 10663019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.